Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook
February 1, 2021 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $2.51, $0.08 worse than the analyst estimate of $2.59. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.58 billion.
"Our achievements in 2020 were marked by a significant increase in the number of... More
